Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Approved
Current status date:
2021-08-12
Product name:
TARO-MEDROXYPROGESTERONE INJECTION
DIN:
02519062
Product Monograph/Veterinary Labelling:
Date:
2023-07-13
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
TARO PHARMACEUTICALS INC
130 East Drive
Brampton
Ontario
Canada
L6T 1C1
Class:
Human
Dosage form(s):
Suspension
Route(s) of administration:
Intramuscular
Number of active ingredient(s):
1
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
68:12.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
G03AC06 MEDROXYPROGESTERONE
Active ingredient group (AIG) number:See footnote5
0106339003
| Active ingredient(s) | Strength |
|---|---|
| MEDROXYPROGESTERONE ACETATE | 150 MG / ML |